AOP Orphan announces 5-year results on BESREMi® in PV at the ASH Annual Meeting 2020

[Manouche]

Besremi showed clear advantages in efficacy and safety/tolerability versus best-available-treatment (mostly hydroxyurea) in this long-term treatment analysis in the randomized-controlled setting.

* Freedom of phlebotomy with hematocrit below 45% was achieved in 81.8% of patients receiving Besremi vs. only 63.2% in the control group (p=0.01).

* Mutant JAK2 allele burden decreased from 37.3% at baseline to 7.3% in patients receiving Besremi indicating disease modification, while it increased from 38.1% to 42.6% in the control group (p<0.0001).

* Disease progression was reduced to 0.2%-per-patient year (one case of myelofibrosis) in patients receiving Besremi vs. 1.0%-per-patient year observed in the control group (two cases of transformation to acute leukemia and two cases of myelofibrosis).

edomexaldia.com/2020/12/06/...

[MPort]

Who receives Besrimi in UK? I mean in general. We are aware of venesections, hydra and interferon use. Do you know if it used for PV or ET? This is new to me.

[Manouche in reply to MPort]

Not yet, but hopefully it should be available in the UK within the next couple of years.

[Lena70 in reply to MPort]

For PV. ema.europa.eu/en/medicines/...

[MPort in reply to Lena70]

Thank you. That is very helpful. So its a type of interferon and is not generally available here.

[Bluetop in reply to Lena70]

Thanks. This the first paper I have seen which talks about the possible side effects of Ropeg.

[Bluetop]

Thanks for posting. It does seem that a strong case is developing in favour of Ropeg. Yet, as of my last appointment with Haem, still the advice was to stick with hydroxy.

[dpoe in reply to Bluetop]

I would find another doctor.Interferon A is in almost every circumstance, superior to hydroxyurea.